Aarti Drugs · NSE: AARTIDRUGS · BSE: 524348
Q3 FY23 results · Oct–Dec 2022
Aarti Drugs reported revenue from operations of ₹663.96 crore (up 4.6% from Q3 FY22) and net profit of ₹36.67 crore (down 37.1% from Q3 FY22) for Q3 FY23 (Oct–Dec 2022), on a consolidated basis.
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 663.96 | 634.80 | +4.6% | 687.72 | −3.5% |
| Other income | 1.01 | 6.66 | −84.8% | 0.05 | 20x |
| Total income | 664.97 | 641.46 | +3.7% | 687.77 | −3.3% |
| Profit before tax | 49.68 | 78.69 | −36.9% | 53.19 | −6.6% |
| Net profit for the period | 36.67 | 58.28 | −37.1% | 38.74 | −5.3% |
| Attributable to shareholders of the company | 36.68 | 58.29 | −37.1% | 38.75 | −5.3% |
| EPS, basic (₹) | 3.96 | 6.29 | −37.0% | 4.18 | −5.3% |
| Net margin (%) | 5.5 | 9.2 | 5.6 |
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 625.53 | 593.21 | +5.4% | 624.83 | +0.1% |
| Other income | 0.97 | 1.62 | −40.1% | 0.09 | +977.8% |
| Total income | 626.50 | 594.83 | +5.3% | 624.92 | +0.3% |
| Profit before tax | 48.96 | 75.35 | −35.0% | 50.08 | −2.2% |
| Net profit for the period | 36.71 | 55.85 | −34.3% | 36.58 | +0.4% |
| EPS, basic (₹) | 3.96 | 6.03 | −34.3% | 3.95 | +0.3% |
| Net margin (%) | 5.9 | 9.4 | 5.9 |
Consolidated
- Filed with BSE
- 28 Jan 2023, 17:07 IST
- Board meeting
- 27 Jan 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 28 Jan 2023, 17:07 IST
- Board meeting
- 27 Jan 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Audited
- Source
- XBRL filing on BSE